Orgenesis (ORGS) Stock Price, News & Analysis

Company Overview

Orgenesis Inc. is a biotechnology company focused on cell and gene therapy development and the technologies needed to manufacture these treatments closer to the point of patient care. Its work combines therapeutic programs with bioprocessing systems intended to support the production of personalized, autologous cell therapies.

The company’s technology platform includes its Point-of-Care (POCare) ecosystem and Mobile Processing Units (MPUs). These systems are designed to provide controlled, modular environments for processing patient-derived cells at hospitals, clinics, and other treatment sites, with the goal of reducing reliance on centralized manufacturing facilities.

Orgenesis has pursued collaborations with academic institutions, healthcare organizations, and biotechnology partners in the United States and internationally. The company was founded in 2011, and Vered Caplan has served as its chief executive officer. Its activities have included research and development programs involving regenerative medicine and cell-based therapies, although the status and scope of individual programs may change over time.

Key Stats

• Today's Range: $0.38 to $0.38
• 50-Day Range: $0.00 to $0.67
• 52-Week Range: $0.00 to $0.85
• Volume: 110 shs
• Average Volume: 1,085 shs
• Market Capitalization: $1.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Orgenesis Stock Analysis - MarketRank™

Orgenesis scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Orgenesis.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Orgenesis is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Orgenesis is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.10% of the float of Orgenesis has been sold short.

Short Interest Ratio / Days to Cover

Orgenesis has a short interest ratio ("days to cover") of 1.24, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Orgenesis does not currently pay a dividend.

Dividend Growth

Orgenesis does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Orgenesis this week, compared to 0 articles on an average week.

MarketBeat Follows

2 people have added Orgenesis to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Orgenesis insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.91% of the stock of Orgenesis is held by insiders.

Percentage Held by Institutions

22.56% of the stock of Orgenesis is held by institutions.

Company Calendar

• Today: 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:ORGS
• Previous Symbol: NASDAQ:ORGS
• CIK: 1460602
• Web: www.orgenesis.com
• Phone: (480) 659-6404
• Fax: N/A
• Employees: 150
• Year Founded: 2008

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $662 thousand
• Price / Sales: 2.93
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($7.26) per share
• Price / Book: -0.05

Miscellaneous

• Outstanding Shares: 5,170,000
• Free Float: N/A
• Market Cap: $1.94 million
• Optionable: No Data
• Beta: 3.63